The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Increased Mortality and Cardiovascular Morbidity Associated With Use of Nonsteroidal Anti-inflammatory Drugs in Chronic Heart Failure
Abstract
BACKGROUND: Accumulating evidence indicates increased cardiovascular risk associated with nonsteroidal anti-inflammatory drug (NSAID) use, in particular in patients with established cardiovascular disease. We studied the risk of death and hospitalization because of acute myocardial infarction and heart failure (HF) associated with use of NSAIDs in an unselected cohort of patients with HF. METHODS: We identified 107,092 patients surviving their first hospitalization because of HF between January 1, 1995, and December 31, 2004, and their subsequent use of NSAIDs from individual-level linkage of nationwide registries of hospitalization and drug dispensing by pharmacies in Denmark. Data analysis was performed using Cox proportional hazard models adjusted for age, sex, calendar year, comorbidity, medical treatment, and severity of disease, and propensity-based risk-stratified models and case-crossover models. RESULTS: A total of 36,354 patients (33.9%) claimed at least 1 prescription of an NSAID after discharge; 60,974 (56.9%) died, and 8970 (8.4%) and 39,984 (37.5%) were hospitalized with myocardial infarction or HF, respectively. The hazard ratio (95% confidence interval) for death was 1.70 (1.58-1.82), 1.75 (1.63-1.88), 1.31 (1.25-1.37), 2.08 (1.95-2.21), 1.22 (1.07-1.39), and 1.28 (1.21-1.35) for rofecoxib, celecoxib, ibuprofen, diclofenac, naproxen, and other NSAIDs, respectively. Furthermore, there was a dose-dependent increase in risk of death and increased risk of hospitalization because of myocardial infarction and HF. Propensity-based risk-stratified analysis and case-crossover models yielded similar results. CONCLUSIONS: NSAIDs are frequently used in patients with HF and are associated with increased risk of death and cardiovascular morbidity. Inasmuch as even commonly used NSAIDs exerted increased risk, the balance between risk and benefit requires careful consideration when any NSAID is given to patients with HF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,154
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., et al. (2000) · JAMA · doi:10.1001/jama.284.10.1247 · Cited by 3,154
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
The Case-Crossover Design: A Method for Studying Transient Effects on the Risk of Acute Events
Maclure, M. (1991) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115853 · Cited by 2,327 · cited 1×
“Furthermore, to ensure the robustness of our findings, the analyses were repeated using casecrossover models.(20) The case-crossover analysis includes only patients experiencing an event; however, rather than using matched control subjects, the case serves as its own control, thereby reducing the effect of unmeasured…”
MethodGuidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)
Swedberg, K., Cleland, J., Dargie, H., Drexler, H., Follath, F., Komajda, M., Tavazzi, L., Smiseth, O. A., Gavazzi, A., Haverich, A., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi204 · Cited by 2,260
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006) · BMJ · doi:10.1136/bmj.332.7553.1302 · Cited by 1,445
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003199 · Cited by 1,394
McGettigan, P., & Henry, D. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60011 · Cited by 1,096
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Grosser, T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27291 · Cited by 1,027
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804
Hippisley-Cox, J., & Coupland, C. (2005) · BMJ · doi:10.1136/bmj.330.7504.1366 · Cited by 561
Gislason, G. H., Jacobsen, S., Rasmussen, J. N., Rasmussen, S., Buch, P., Friberg, J., Schramm, T. K., Abildstrom, S. Z., Køber, L., Madsen, M., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.616219 · Cited by 447
Self-citationMamdani, M., Juurlink, D. N., Lee, D. S., Rochon, P. A., Kopp, A., Naglie, G., Austin, P. C., Laupacis, A., & Stukel, T. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16299-5 · Cited by 435
Relation of Loop Diuretic Dose to Mortality in Advanced Heart Failure
Eshaghian, S., Horwich, T. B., & Fonarow, G. C. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.072 · Cited by 410
Lee, D. S., Donovan, L., Austin, P. C., Gong, Y., Liu, P. P., Rouleau, J. L., & Tu, J. V. (2005) · Medical Care · doi:10.1097/00005650-200502000-00012 · Cited by 358
Meta-analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure
(2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.5.ioi50013 · Cited by 329
Gislason, G. H., Rasmussen, J. N., Abildstrøm, S. Z., Gadsbøll, N., Buch, P., Friberg, J., Rasmussen, S., Køber, L., Stender, S., Madsen, M., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi705 · Cited by 301
Self-citationJohnsen, S. P. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.9.978 · Cited by 288
Cyclooxygenase Inhibition and Cardiovascular Risk
Antman, E. M., DeMets, D., & Loscalzo, J. (2005) · Circulation · doi:10.1161/circulationaha.105.568451 · Cited by 282
Solomon, S. D., Pfeffer, M. A., McMurray, J. J. V., Fowler, R., Finn, P., Levin, B., Eagle, C., Hawk, E., Lechuga, M., Zauber, A. G., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.636746 · Cited by 273
Accuracy of a Heart Failure Diagnosis in Administrative Registers
Kümler, T., Gislason, G. H., Kirk, V., Bay, M., Nielsen, O. W., Køber, L., & Torp-Pedersen, C. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.05.006 · Cited by 263
Self-citationWatson, D. J., Rhodes, T., Cai, B., & Guess, H. A. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1105 · Cited by 238
Nonsteroidal Anti-inflammatory Drug Use and Acute Myocardial Infarction
Solomon, D. H., Glynn, R. J., Levin, R., & Avorn, J. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1099 · Cited by 234
Nuttall, M., van der Meulen, J., & Emberton, M. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.07.015 · Cited by 219
Helin-Salmivaara, A. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl053 · Cited by 211
Association Between Naproxen Use and Protection Against Acute Myocardial Infarction
Rahme, E., Pilote, L., & LeLorier, J. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1111 · Cited by 203
Gislason, G. H., Rasmussen, J. N., Abildstrom, S. Z., Schramm, T. K., Hansen, M. L., Buch, P., Sørensen, R., Folke, F., Gadsbøll, N., Rasmussen, S., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.669101 · Cited by 183
Self-citationADAPT Research Group (2006) · PLoS Clinical Trials · doi:10.1371/journal.pctr.0010033 · Cited by 176
Hudson, M., Richard, H., & Pilote, L. (2005) · BMJ · doi:10.1136/bmj.330.7504.1370 · Cited by 164
Prostacyclin protects against elevated blood pressure and cardiac fibrosis
Francois, H., Athirakul, K., Howell, D. N., Dash, R., Mao, L., Kim, H., Rockman, H. A., FitzGerald, G. A., Koller, B. H., & Coffman, T. M. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.08.005 · Cited by 151
Marked Interindividual Variability in the Response to Selective Inhibitors of Cyclooxygenase-2
Fries, S., Großer, T., Price, T. S., Lawson, J. A., Kapoor, S. C., DeMarco, S., Pletcher, M. T., Wiltshire, T., & FitzGerald, G. A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.002 · Cited by 138
Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2005.02.069 · Cited by 137
Farkouh, M. E., Greenberg, J., Jeger, R. V., Ramanathan, K., Verheugt, F. W. A., Chesebro, J. H., Kirshner, H. S., Hochman, J. S., Lay, C. L., Ruland, S. D., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.066001 · Cited by 119
Taubert, K. A., Antman, E. M., BENNETT, J. S., Daugherty, A., Furberg, C. D., & Roberts, H. R. (2007) · Cited by 112
Timmers, L., Sluijter, J. P. G., Verlaan, C. W. J., Paul Steendijk, A., Cramer, M. J., Emons, M., Strijder, C. F., Gründeman, P. F., Sze, S. K., Hua, L., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.647230 · Cited by 106
Huerta, C., Varas‐Lorenzo, C., Castellsagué, J., & Rodriguez, L. A. G. (2006) · Heart · doi:10.1136/hrt.2005.082388 · Cited by 102
THIERS, B. H. (2007) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70535-5 · Cited by 84
The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction
Brophy, J. M., Lévesque, L. E., & Zhang, B. (2006) · Heart · doi:10.1136/hrt.2006.089367 · Cited by 69
Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors
Lévesque, L. E. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.051679 · Cited by 68
Hudson, M., Rahme, E., Richard, H., & Pilote, L. (2007) · Arthritis Care & Research · doi:10.1002/art.22614 · Cited by 52
Hudson, M., Baron, M. G., Rahme, E., & Pilote, L. (2005) · PubMed · Cited by 48
Mamdani, M., Juurlink, D. N., & Lee, D. S. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.07.129 · Cited by 33
Accuracy of a heart failure diagnosis in administrative registers
KUMLER, T., Gislason, G., Kirk, V., BAY, M., Nielsen, O. W., Køber, L., & TORPPEDERSEN, C. (2008) · European Journal of Heart Failure Supplements · doi:10.1016/s1567-4215(08)60430-0 · Cited by 14
Self-citationMeta-analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure
Elliott, W. J. (2006) · Yearbook of Cardiology · doi:10.1016/s0145-4145(07)70029-1 · Cited by 8
Cited by
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8807 · Cited by 3,304
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8776 · Cited by 2,106
Metadata
- Authors
- Gislason, G. H., Rasmussen, J. N., Abildstrom, S. Z., Schramm, T. K., Hansen, M. L., Fosbøl, E. L., Sørensen, R., Folke, F., Buch, P., Gadsbøll, N., Rasmussen, S., Poulsen, H. E., Køber, L., Madsen, M., & Torp-Pedersen, C.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2009-01-26
- Volume
- 169
- Issue
- 2
- Pages
- 141
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2139373014
- Cited by
- 295
- References
- 51
- FWCI
- 18.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.